Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Autor: Hallek M, Fischer K, Fingerle Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Caligaris Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group, ZINZANI, PIER LUIGI

On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3c4dca5ee9ecb5b3880f0a5f2749b0d
http://hdl.handle.net/11585/99853

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial.

Autor: Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner CM, Eichhorst BF, Döhner H, Hallek MJ, Kneba M

Publikováno v: Journal of Clinical Oncology; 3/20/2012, Vol. 30 Issue 9, p980-988, 9p

Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab.

Autor: Kater AP; Department of Hematology, Cancer Center Amsterdam, LYMMCARE, Amsterdam University Medical Centers University of Amsterdam Amsterdam The Netherlands., Eichhorst BF; Department of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Dusseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany., Owen CJ; Departments of Medicine and Oncology University of Calgary Calgary Alberta Canada., Jaeger U; Clinical Department of Hematology and Hemostaseology Medical University of Vienna Vienna Austria., Chyla B; AbbVie North Chicago Illinois USA., Lefebure M; Roche Products Ltd Welwyn Garden City UK., Millen R; Roche Products Ltd Welwyn Garden City UK., Jiang Y; Genentech Inc. South San Francisco California USA., Thadani-Mulero M; Roche Products Ltd Welwyn Garden City UK., Boyer M; Roche Products Ltd Welwyn Garden City UK., Seymour JF; Peter MacCallum Cancer Centre Royal Melbourne Hospital and University of Melbourne Melbourne Australia.

Publikováno v: HemaSphere [Hemasphere] 2024 Aug 27; Vol. 8 (8), pp. e146. Date of Electronic Publication: 2024 Aug 27 (Print Publication: 2024).

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial.

Autor: von Tresckow J; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany. Julia.vontresckow@uk-essen.de.; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Julia.vontresckow@uk-essen.de., Cramer P; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Robrecht S; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Langerbeins P; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Fink AM; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Al-Sawaf O; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Fürstenau M; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Illmer T; BAG Freiberg-Richter, Jacobasch, Wolf, Illmer, Dresden, Germany., Klaproth H; Hämatologische/ Onkologische Praxis Dr. Klaproth, Neunkirchen, Germany., Tausch E; Department of Internal Medicine III, Ulm University, Ulm, Germany., Ritgen M; Department of Medicine II, University of Schleswig-Holstein, Kiel, Germany., Fischer K; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Wendtner CM; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany.; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany., Kreuzer KA; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Stilgenbauer S; Department of Internal Medicine III, Ulm University, Ulm, Germany.; Department of Internal Medicine I, Saarland University, Homburg, Germany., Böttcher S; Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School Rostock, Rostock, Germany., Eichhorst BF; Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German CLL Study Group, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany., Hallek M; Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, CECAD Cluster of Excellence at the University of Cologne, Clinical Research Unit (KFO) 286, German CLL Study Group, University of Cologne, Cologne, Germany.

Publikováno v: Leukemia [Leukemia] 2022 Aug; Vol. 36 (8), pp. 2125-2128. Date of Electronic Publication: 2022 Jun 25.